SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes.
Aust Fam Physician
; 42(10): 706-10, 2013 Oct.
Article
em En
| MEDLINE
| ID: mdl-24130972
ABSTRACT
BACKGROUND:
Because of the progressive nature of the disease, most patients with type 2 diabetes mellitus eventually require multiple treatments to achieve glycaemic targets. The majority of available therapies are insulin dependent, aiming to decrease insulin resistance and increase insulin secretion. Sodium glucose co-transporter 2 (SGLT2) inhibitors, a new class of antidiabetic agents, limit renal glucose reabsorption promoting urinary excretion of glucose, thereby reducing plasma glucose.OBJECTIVE:
This article explores the mechanism of action and clinical data surrounding SGLT2 inhibitors, with a particular focus on dapagli-flozin.CONCLUSION:
Clinical trials have shown dapagliflozin to be effective in reducing glycosylated haemoglobin, weight and fasting plasma glucose, either as monotherapy or as add-on therapy to metformin, sulphonylurea and insulin. Other SGLT2 inhibitors are currently under investigation.
Buscar no Google
Bases de dados:
MEDLINE
Assunto principal:
Diabetes Mellitus Tipo 2
/
Inibidores do Transportador 2 de Sódio-Glicose
/
Glucosídeos
/
Hipoglicemiantes
Limite:
Humans
Idioma:
En
Revista:
Aust Fam Physician
Ano de publicação:
2013
Tipo de documento:
Article